About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Journal of Immunotherapy
›
top-articles
Journal of Immunotherapy
3.3
(top 10%)
impact factor
3.1K
(top 10%)
papers
73.8K
(top 5%)
citations
114
(top 5%)
h
-index
3.5
(top 10%)
impact factor
3.3K
all documents
76.9K
doc citations
172
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Journal of Immunotherapy
2013
953
2
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Journal of Immunotherapy
2010
950
3
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
Journal of Immunotherapy
2007
656
4
Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients
Journal of Immunotherapy
2003
598
5
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Journal of Immunotherapy
2013
460
6
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
Journal of Immunotherapy
2010
420
7
IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells
Journal of Immunotherapy
2006
397
8
Induction of Cytokine Production from Human Monocytes Stimulated with Alginate
Journal of Immunotherapy
1991
347
9
Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma
Journal of Immunotherapy
2001
337
10
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Journal of Immunotherapy
2009
336
11
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Journal of Immunotherapy
2015
333
12
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
Journal of Immunotherapy
2002
326
13
Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer
Journal of Immunotherapy
2005
315
14
Vitiligo in Patients with Melanoma
Journal of Immunotherapy
1996
308
15
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
Journal of Immunotherapy
2009
301
16
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Journal of Immunotherapy
2013
299
17
Cancer and Inflammation: Promise for Biologic Therapy
Journal of Immunotherapy
2010
293
18
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
Journal of Immunotherapy
2011
281
19
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
Journal of Immunotherapy
2005
270
20
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Journal of Immunotherapy
2011
270
21
Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy
Journal of Immunotherapy
2009
269
22
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
Journal of Immunotherapy
2012
269
23
Human Immune Respone to Monoclonal Antibodies
Journal of Immunotherapy
1994
267
24
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Journal of Immunotherapy
2007
260
25
The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors
Journal of Immunotherapy
2005
258
26
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Journal of Immunotherapy
2006
246
27
Immune Suppression in the Tumor Microenvironment
Journal of Immunotherapy
2006
242
28
Sorting Through Subsets
Journal of Immunotherapy
2012
237
29
Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy
Journal of Immunotherapy
2008
236
30
Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
Journal of Immunotherapy
2010
236
31
Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells
Journal of Immunotherapy
2001
234
32
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Journal of Immunotherapy
2019
231
33
The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma
Journal of Immunotherapy
1996
221
34
Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy
Journal of Immunotherapy
2005
217
35
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Journal of Immunotherapy
2008
216
36
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity
Journal of Immunotherapy
2006
214
37
Cytokines and Immune Response in the Tumor Microenvironment
Journal of Immunotherapy
2001
212
38
Identification of T-Cell Epitopes
Journal of Immunotherapy
1993
210
39
Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy
Journal of Immunotherapy
1997
202
40
Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
Journal of Immunotherapy
2010
201
41
Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12
Journal of Immunotherapy
2004
199
42
CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2
Journal of Immunotherapy
2005
199
43
Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy
Journal of Immunotherapy
2005
198
44
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Journal of Immunotherapy
2008
197
45
Myeloid-derived Suppressor Cells in Cancer Patients
Journal of Immunotherapy
2012
195
46
Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy
Journal of Immunotherapy
2010
190
47
Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes
Journal of Immunotherapy
2002
189
48
Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma
Journal of Immunotherapy
2005
189
49
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies
Journal of Immunotherapy
2001
188
50
Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression
Journal of Immunotherapy
2004
188
site/software ©
exaly
; All materials licenced under
CC by-SA
.